Diaceutics PLC

AIM:DXRX Stock Report

Market Cap: UK£118.4m

Diaceutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

AIM:DXRX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
01 Sep 25BuyUK£150Jordan ClarkIndividual107UK£1.40
01 Sep 25BuyUK£150Susanne MunkstedIndividual107UK£1.40
01 Sep 25BuyUK£150Jillian BeggsIndividual107UK£1.40
01 Sep 25BuyUK£150Nicholas RobertsIndividual107UK£1.40
13 May 25SellUK£630,000Peter KeelingIndividual500,000UK£1.26
28 Apr 25BuyUK£150Jordan ClarkIndividual126UK£1.19
28 Apr 25BuyUK£147Susanne MunkstedIndividual124UK£1.19
28 Apr 25BuyUK£150Jillian BeggsIndividual126UK£1.19
28 Apr 25BuyUK£150Nicholas RobertsIndividual126UK£1.19
28 Feb 25BuyUK£150Jordan ClarkIndividual103UK£1.46
28 Feb 25BuyUK£143Susanne MunkstedIndividual98UK£1.46
28 Feb 25BuyUK£150Jillian BeggsIndividual103UK£1.46
28 Feb 25BuyUK£150Nicholas RobertsIndividual103UK£1.46
30 Jan 25BuyUK£16,009Graham PatersonIndividual11,643UK£1.38
28 Jan 25BuyUK£150Jordan ClarkIndividual104UK£1.44
28 Jan 25BuyUK£145Susanne MunkstedIndividual101UK£1.44
28 Jan 25BuyUK£150Nicholas RobertsIndividual104UK£1.44
02 Jan 25BuyUK£150Nicholas RobertsIndividual114UK£1.32
02 Jan 25BuyUK£150Jordan ClarkIndividual114UK£1.32
02 Jan 25BuyUK£144Susanne MunkstedIndividual109UK£1.32

Insider Trading Volume

Insider Buying: DXRX insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of DXRX?
Owner TypeNumber of SharesOwnership Percentage
Private Companies99,2980.117%
Public Companies178,1080.211%
State or Government877,1921.04%
General Public9,210,90210.9%
VC/PE Firms13,818,50016.3%
Individual Insiders19,818,47823.4%
Institutions40,546,38648%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 80.6% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
18%
Peter Keeling
15,252,049UK£21.4m0%no data
16.3%
Gresham House Asset Management Limited
13,818,500UK£19.3m11.7%1.25%
6.55%
Canaccord Genuity Asset Management Limited
5,539,000UK£7.8m-30.2%0.44%
3.54%
Ryan Keeling
2,990,643UK£4.2m0%no data
3.53%
BlackRock, Inc.
2,982,154UK£4.2m14.7%no data
3.01%
West Elk Capital, LLC
2,543,281UK£3.6m0%27.46%
2.92%
Maven Capital Partners UK LLP
2,472,000UK£3.5m0%1.45%
2.87%
Octopus Investments Limited
2,426,968UK£3.4m0%0.25%
2.74%
Danske Capital Denmark
2,313,125UK£3.2m-7.84%0.02%
1.89%
River Global Investors LLP
1,600,000UK£2.2m53.1%0.14%
1.87%
Orange River Management LP
1,580,000UK£2.2m-1.56%9.45%
1.81%
Danske Invest Management A/S
1,534,320UK£2.1m0%0.36%
1.74%
Hargreaves Lansdown Asset Management Ltd.
1,474,364UK£2.1m2.5%0.01%
1.73%
BNY Mellon Advisors, Inc.
1,462,024UK£2.0m4.8%0.01%
1.69%
Edentree Asset Management Limited
1,430,500UK£2.0m0%0.37%
1.51%
Columbia Management Investment Advisers, LLC
1,276,929UK£1.8m0%no data
1.26%
London Wealth Management Limited
1,068,154UK£1.5m22.3%0.08%
1.12%
Castlefield Investments
950,058UK£1.3m0%0.27%
1.07%
Herald Investment Management Ltd.
906,000UK£1.3m0%0.1%
1.04%
Handelsbanken Asset Management
877,200UK£1.2m-10.9%no data
1.04%
Invest Northern Ireland
877,192UK£1.2m0%no data
0.85%
Jefferies Group LLC, Asset Management Arm
722,109UK£1.0m-31.8%0.2%
0.85%
Danske Invest Rahastoyhtio Oy
720,288UK£1.0m-13.3%2.29%
0.84%
Joh. Berenberg, Gossler & Co. KG, Asset Management Arm
713,741UK£999.2k-13.9%0.05%
0.73%
Aberdeen Group Plc
619,843UK£867.8k-14.1%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/03 03:10
End of Day Share Price 2025/09/03 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Diaceutics PLC is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hayley PalmerCanaccord Genuity
Simon StrongCavendish Historical (Cenkos Securities)
Julie SimmondsPanmure Liberum